The first Neuralink patient has passed the 100-day milestone since the Elon Musk founded company's chip was implanted in his brain.
Noland Arbaugh is now ready to begin earning money or raising money as his story grows in popularity.
What Happened: Arbaugh, who was previously the anonymous Neuralink patient, is now publicly known and has done a series of interviews with Bloomberg, "Good Morning America," and several social media influencers.
The 30-year-old has shared details of his accident and spinal cord injury and how Neuralink has supported his everyday life for the better.
"Once you get a taste for using it, you just can't stop. It blows my mind so much," Arbaugh recently said.
Now able to play games, shop, select audiobooks and do more activities, Arbaugh is ready to take the next step.
"I would like to find some way to provide for myself long-term, build a house for me and my family if I can, and not be a burden on those around me any longer," Arbaugh tweeted.
The tweet included a poll with several choices, with the following results at the time of writing.
Monetize Accounts: 17.7%
Streaming: 22.0%
GoFundMe: 4.2%
All of the Above: 56.1%
Musk chimed in with a response of "all" before adding that he recommends the "first two first."
Arbaugh has around 94,000 followers on X, formerly known as Twitter. With the Neuralink device, Arbaugh is able to play games like chess and "Civilization VI" which could open up streaming opportunities for him.
Why It's Important: Due to his condition, Arbaugh was not able to get a job previously and the results of the poll and follow-up could become a strong case study for Neuralink.
"I can control a computer just like anyone else can, which is not something I was able to do beforehand," Arbaugh told "Good Morning America."
Neuralink was recently approved by the FDA for a second human brain chip implant according to a report. The company is hoping to implant the second patient in June from 100 qualifying candidates selected.
The company plans to implant 10 patients this year. Neuralink also plans to seek regulatory approval in new markets including Canada and the United Kingdom in the future.
Photo courtesy: Shutterstock
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.